{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:00:33Z","timestamp":1793383233787,"version":"4.5.0"},"reference-count":36,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2026,4,16]]},"DOI":"10.1080\/10428194.2026.2628205","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:51:28Z","timestamp":1772733088000},"page":"1055-1065","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Real-world treatment patterns, patient characteristics, and outcomes of initial cBTKi-based therapies in second-line or later amongst a contemporary cohort of patients with MCL in the United States"],"prefix":"10.1080","volume":"67","author":[{"given":"Kami","family":"Maddocks","sequence":"first","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center","place":["Columbus, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha","family":"Tracey","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Winfree","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Hall Panjic","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J. M.","family":"Brnabic","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"He","sequence":"additional","affiliation":[{"name":"Syneos Health","place":["Morrisville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University","place":["Atlanta, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4345"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.07.014"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000464"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70233"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70073"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00146"},{"key":"e_1_3_5_8_1","unstructured":"U.S. Food and Drug Administration: FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma. U.S. Food and Drug Administration. 16 January 2025 Accessed 05 January 2026 https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-acalabrutinib-bendamustine-and-rituximab-previously-untreated-mantle-cell-lymphoma."},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00690"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00184-3"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0048"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000418"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.024224"},{"key":"e_1_3_5_14_1","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron health, SEER, and NPCR","author":"Ma X","year":"2020","unstructured":"Ma X, Long L, Moon S, et\u00a0al. Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron health, SEER, and NPCR. medRxiv. 2020;1\u201360.","journal-title":"medRxiv"},{"key":"e_1_3_5_15_1","article-title":"Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research","author":"Birnbaum B","year":"2020","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et\u00a0al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. ArXiv. 2020;1\u201325.","journal-title":"ArXiv"},{"key":"e_1_3_5_16_1","volume-title":"Inc SI: SAS Enterprise Guide (Version 8.2)","year":"2020","unstructured":"Inc SI: SAS Enterprise Guide (Version 8.2). Computer Software; 2020. Cary, NC: SAS Institute Inc."},{"key":"e_1_3_5_17_1","volume-title":"R Core Team: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing","year":"2023","unstructured":"R Core Team: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. 2023. https:\/\/www.R-project.org"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8262787"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2565829"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007247"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061207"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02698"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004765"},{"key":"e_1_3_5_24_1","unstructured":"U.S. Food and Drug Administration: FDA grants accelerated approval to acalabrutinib for mantle cell lymphoma. U.S. Food and Drug Administration. 31 October ; 2017 Accessed 05 January 2026 https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-acalabrutinib-mantle-cell-lymphoma."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01252-4"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2536612"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17363"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01013-3"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023525"},{"key":"e_1_3_5_30_1","volume-title":"Real-world treatment outcomes among relapsed\/refractory patients with mantle cell lymphoma treated with ibrutinib or acalabrutinib, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Annual Meeting","author":"Crawford S","year":"2023","unstructured":"Crawford S, Lafeuille M-H, Emond B, et\u00a0al. Real-world treatment outcomes among relapsed\/refractory patients with mantle cell lymphoma treated with ibrutinib or acalabrutinib, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Annual Meeting. International Society for Pharmacoeconomics and Outcomes Research (ISPOR): Boston, MA, May 7-10; 2023."},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017160"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009804"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2554354"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-665"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029734"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0976"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2026.2628205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:53:12Z","timestamp":1776790392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2026.2628205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,16]]}},"alternative-id":["10.1080\/10428194.2026.2628205"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2026.2628205","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}